Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Measurement of Cancer Cell Growth Heterogeneity through Lentiviral Barcoding Identifies Clonal Dominance as a Characteristic of In Vivo Tumor Engraftment.

Nolan-Stevaux O, Tedesco D, Ragan S, Makhanov M, Chenchik A, Ruefli-Brasse A, Quon K, Kassner PD.

PLoS One. 2013 Jun 26;8(6):e67316. doi: 10.1371/journal.pone.0067316. Print 2013.

2.

Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.

Nolan-Stevaux O, Zhong W, Culp S, Shaffer K, Hoover J, Wickramasinghe D, Ruefli-Brasse A.

PLoS One. 2012;7(12):e50920. doi: 10.1371/journal.pone.0050920. Epub 2012 Dec 27.

3.

Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.

Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):E1275-84. doi: 10.1073/pnas.1111079108. Epub 2011 Nov 14.

4.

Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes.

Nolan-Stevaux O, Truitt MC, Pahler JC, Olson P, Guinto C, Lee DC, Hanahan D.

Genes Cancer. 2010 Feb;1(2):125-41. doi: 10.1177/1947601909358722.

5.

GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation.

Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M, Fernández-Zapico ME, Hanahan D.

Genes Dev. 2009 Jan 1;23(1):24-36. doi: 10.1101/gad.1753809.

Supplemental Content

Loading ...
Support Center